Compare PARR & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PARR | BLLN |
|---|---|---|
| Founded | 1984 | 2016 |
| Country | United States | United States |
| Employees | N/A | 713 |
| Industry | Integrated oil Companies | Medical Specialities |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.9B |
| IPO Year | 2000 | N/A |
| Metric | PARR | BLLN |
|---|---|---|
| Price | $65.28 | $76.16 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 7 |
| Target Price | $70.17 | ★ $126.71 |
| AVG Volume (30 Days) | ★ 1.3M | 372.4K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1313.56 | N/A |
| EPS | ★ 7.16 | N/A |
| Revenue | ★ $2,443,066,000.00 | N/A |
| Revenue This Year | N/A | $46.29 |
| Revenue Next Year | $3.78 | $30.14 |
| P/E Ratio | $9.17 | ★ N/A |
| Revenue Growth | ★ 30.99 | N/A |
| 52 Week Low | $14.01 | $61.96 |
| 52 Week High | $68.00 | $138.70 |
| Indicator | PARR | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 57.79 | 45.20 |
| Support Level | $34.55 | $64.99 |
| Resistance Level | $67.39 | $83.20 |
| Average True Range (ATR) | 3.13 | 6.09 |
| MACD | -0.13 | -1.22 |
| Stochastic Oscillator | 80.93 | 23.02 |
Par Pacific Holdings Inc is an oil and gas company that manages and maintains interests in energy and infrastructure businesses. The company has three reportable segments: Refining. Under its refining business, the company produces ultra-low-sulfur diesel, gasoline, jet fuel, marine fuel, LSFO, and other associated refined products. Its Retail includes operating licenses out brands to serve the retail consumer. Through the Logistics segment, crude shipments are delivered to the refineries, in addition to finished products that are exported. It generates maximum revenue from the Refining segment.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.